Antibody-mediated Rejection
38
5
10
15
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
13.2%
5 terminated out of 38 trials
75.0%
-11.5% vs benchmark
18%
7 trials in Phase 3/4
40%
6 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (38)
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
CD38 mAb Induction + Azathioprine Maintenance for Chronic Active AMR in Kidney Transplant Recipients
VIRTUUS Children's Study
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS
Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
Biorepository and Registry for Plasma Exchange Patients
Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT
Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
Isatuximab in Lung Transplant Recipients
TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection
A Prospective Randomized Trial of ECP in Subclinical AMR
Felzartamab in Late Antibody-Mediated Rejection
Desensitization in Kidney Allograft Using Daratumumab